Opposing effects of RAS on p53: Transcriptional activation of mdm2 and induction of p19(ARF)

Cell

Volumn 103, Issue 2, 2000, Pages 321-330

  Ries, Stefan ^a   Biederer, Carola ^a   Woods, Douglas ^a   Shifman, Ohad ^b   Shirasawa, Senji ^c   Sasazuki, Takehiko ^c   McMahon, Martin ^a   Oren, Moshe ^b   McCormick, Frank ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^c KYUSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE RIBOSYLATION FACTOR; CELL PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN MDM2; PROTEIN P19; PROTEIN P53; RAF PROTEIN; RAS PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL GROWTH; CELL INTERACTION; CELL TRANSFORMATION; CONTROLLED STUDY; DNA DAMAGE; ENZYME ACTIVATION; GENE ACTIVATION; GENE CONTROL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSCRIPTION REGULATION;

ANIMALIA;

EID: 0034644506     PISSN: 00928674     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0092-8674(00)00123-9     Document Type: Article

References (69)

1. Transforming p21 ras mutants and c-Ets-2 activate the cyclin D1 promoter through distinguishable regions
2. A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells
3. mdm2 expression is induced by wild type p53 activity
4. Regulation of mdm2 expression by p53: Alternative promoters produce transcripts with nonidentical translation potential
5. p14ARF links the tumour suppressors RB and p53
6. The basic helix-loop-helix transcription factors myogenin and Id2 mediate specific induction of the caveolin-3 gene expression during embryonic development
7. ras oncogenes in human cancer: A review
8. Requirement for p53 and p21 to sustain G2 arrest after DNA damage
9. The repertoire of fos and jun proteins expressed during the G1 phase of the cell cycle is determined by the duration of mitogen-activated protein kinase activation
10. Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas
11. Mutations of cell cycle regulators, biological and clinical implications for human neoplasia
12. E1A signaling to p53 involves the p19(ARF) tumor suppressor
13. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
14. Hypermethylation-associated inactivation of p14(ARF) is independent of p16(INK4a) methylation and p53 mutational status
15. Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line
16. Diverse signaling pathways activated by growth factor receptors induce broadly overlapping, rather than independent, sets of genes
17. Activated human N-ras oncogene enhances x-irradiation repair of mammalian cells in vitro less effectively at low dose rate. Implications for increased therapeutic ratio of low dose rate irradiation
18. A mutant p53 that discriminates between p53-responsive genes cannot induce apoptosis
19. Splicing into senescence: The curious case of p16 and p19ARF
20. Mdm2 promotes the rapid degradation of p53
21. Therapeutic intervention and signaling
22. p53 mutations in human cancers
23. Association of p19(ARF) with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53
24. K-ras is an essential gene in the mouse with partial functional overlap with N-ras
25. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53
26. Wild type p53 can mediate sequence-specific transactivation of an internal promoter within the mdm2 gene
27. A cell cycle regulator potentially involved in genesis of many tumor types
28. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF
29. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2
30. Signal transduction from multiple Ras effectors
31. Lessons from hereditary colorectal cancer
32. Regulation of p53 stability by Mdm2
33. MDM2 arbiter of p53's destruction
34. Farnesyl transferase inhibitors induce apoptosis of Ras-transformed cells denied substratum attachment
35. N-terminal 130 amino acids of MDM2 are sufficient to inhibit p53-mediated transcriptional activation
36. Insulin-like growth factor-1 induces Mdm2 and down-regulates p53, attenuating the myocyte renin-angiotensin system and stretch-mediated apoptosis
37. The p53 tumour suppressor gene
38. Premature senescence involving p53 and p16 is activated in response to constitutive MEK/MAPK mitogenic signaling
39. Ras target proteins in eukaryotic cells
40. Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein
41. p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features
42. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation
43. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53
44. Cloning and characterization of a second AP-2 transcription factor: AP-2 beta
45. Amplification of a gene encoding a p53-associated protein in human sarcomas
46. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53
47. p19ARF links the tumour suppressor p53 to Ras
48. Ras signalling linked to the cell-cycle machinery by the retinoblastoma protein
49. The p53-mdm2 autoregulatory feedback loop: A paradigm for the regulation of growth control by p53?
50. Oncogene-transformed NIH 3T3 cells display radiation resistance levels indicative of a signal transduction pathway leading to the radiation-resistant phenotype
51. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53
52. Signaling to p53: Breaking the MDM2-p53 circuit
53. Loss of p14ARF facilitates replication of the adenovirus mutant dl1520 (ONYX-015) in tumor cells
54. Role of phosphoinositide 3-OH kinase in cell transformation and control of the actin cytoskeleton by Ras
55. Conditional transformation of cells and rapid activation of the mitogen-activated protein kinase cascade by an estradiol-dependent human raf-1 protein kinase
56. The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines
57. Functional interaction of wild-type and mutant p53 transfected into human tumor cell lines carrying activated ras genes
58. Induction of Mdm2 and enhancement of cell survival by bFGF
59. The ARF/p53 pathway
60. Altered growth of human colon cancer cell lines disrupted at activated Ki-ras
61. The ras oncogenes increase the intrinsic resistance of NIH 3T3 cells to ionizing radiation
62. Activation of Raf as a result of recruitment to the plasma membrane
63. The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2
64. P19(ARF) stabilizes p53 by blocking nucleo-cytoplasmic shuttling of Mdm2
65. Raf-induced proliferation or cell cycle arrest is determined by the level of Raf activity with arrest mediated by p21Cip1
66. The p53mdm-2 autoregulatory feedback loop
67. Interaction between the retinoblastoma protein and the oncoprotein MDM2
68. A functional p53-responsive intronic promoter is contained within the human mdm2 gene
69. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization